In a recent study published in Alzheimer’s Research & Therapy, researchers found encouraging information about reducing antipsychotic use in dementia. Residents who discontinued long-term antipsychotic medications, consistent with clinical guidelines, had lower risks of all-cause hospitalization compared to those who continued taking them. They also had lower risks of hospitalization for pneumonia or urinary tract infection.

What great information! The key, of course, is “consistent with clinical guidelines,” as discontinuing antipsychotic medications can have challenges. That said, there may be meaningful clinical benefits to re-evaluating long-term antipsychotic medications used regularly. The findings also encourage efforts to deprescribe these medications when clinically appropriate for residents living with dementia. The study published in Alzheimer’s Research & Therapy provides more information on the findings and outcomes associated with discontinuation.

Reducing antipsychotic use is not a new idea. However, having information that directly relates to residents living with dementia is valuable. Antipsychotic medications are commonly used to manage this population, but to what end? Regulators are looking closely at the use of these medications. In addition, many of our senior living communities have behavior management committees assessing medication use. But are we doing everything we can to avoid negative outcomes? Maybe, maybe not. Reducing antipsychotic use in dementia may be another great topic for a QAPI discussion.

Include your mental health service provider, attending physicians, pharmacist, and the entire interdisciplinary team in the conversation. Successfully reducing antipsychotic use in even one resident, when clinically appropriate, is a win.

Stay well and stay informed!